Roche punts a PhI can­cer drug out of the pipeline and back to Ory­zon

Lit­tle Ory­zon Ge­nomics in Spain picked up a con­sid­er­able en­dorse­ment and fi­nan­cial sup­port when Roche stepped in three years ago to part­ner on its ly­sine spe­cif­ic demethy­lase-1 (LSD1) in­hibitor ORY-1001 (RG6016) for acute my­loid leukemia and sol­id tu­mors. But it had to give up the deal and the $500 mil­lion in mile­stones that came with it af­ter Roche de­cid­ed to punt it out of the pipeline.

Ac­cord­ing to Ory­zon, the drug didn’t make the cut at the Swiss phar­ma gi­ant as it “repri­or­i­tized” its pipeline. Roche will see through an on­go­ing Phase I study in small cell lung can­cer and then hand it all back to Ory­zon, which plans to car­ry on with the work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.